PURPOSE To evaluate visual outcomes, satisfaction, and spectacle independence in non-presbyopic hyperopic patients who underwent bilateral refractive lens exchange with a trifocal intraocular lens (IOL) and to compare them with presbyopic hyperopic patients. METHODS In this retrospective study, patients younger than 40 years underwent bilateral refractive lens exchange with a diffractive trifocal IOL (FineVision Micro F; PhysIOL SA) for hyperopia with at least 3 months of follow-up. A control group of patients older than 50 years was matched by axial length, sex, and follow-up. Safety, efficacy, predictability, patient satisfaction, and spectacle independence were evaluated. RESULTS One hundred thirty-three patients (average age = 36.94 ± 2.91 years; range = 21.50 to 40 years) were included in this study. After a mean follow-up of 8.83 ± 5.69 months (range = 2.75 to 77.63 months), the safety and efficacy indexes and predictability within ±1.00 diopters (D) were 1.02%, 0.98%, and 99.62%, respectively, which was not different from the control group (P > .05). No intraoperative complications were recorded. The only postoperative complication was posterior capsule opacification in 21 eyes (7.89%), which was similar to the control group (P > .05). Ninety-seven percent of patients in each group expressed that they were satisfied and all of them in each group reported that they did not use spectacles for distance, intermediate, or near vision. CONCLUSIONS Refractive lens exchange and trifocal IOL implantation for hyperopia in patients without presbyopia provided the same good visual outcomes as in presbyopic patients with a high rate of patient satisfaction and spectacle independence. [J Refract Surg. 2021;37(8):524-531.].

中文翻译：

---

双侧屈光性晶状体置换与三焦人工晶状体治疗 40 岁以下远视患者的病例对照研究。

目的 评估用三焦点人工晶状体 (IOL) 进行双侧屈光性晶状体置换的非老花眼远视患者的视力结果、满意度和眼镜独立性，并将其与老花眼远视患者进行比较。方法 在这项回顾性研究中，40 岁以下的患者接受了双侧屈光性晶状体置换术和衍射三焦人工晶状体（FineVision Micro F；PhysIOL SA）治疗远视至少 3 个月的随访。50 岁以上患者的对照组与轴长、性别和随访相匹配。评估了安全性、有效性、可预测性、患者满意度和眼镜独立性。结果 本研究共纳入 133 名患者（平均年龄 = 36.94 ± 2.91 岁；范围 = 21.50 至 40 岁）。经过 8.83 ± 5 的平均随访。69个月（范围=2.75～77.63个月），安全性和有效性指标及±1.00屈光度内的可预测性（D）分别为1.02%、0.98%和99.62%，与对照组无差异（P>. 05）。没有记录术中并发症。术后唯一并发症为后囊膜混浊 21 眼（7.89%），与对照组相似（P > .05）。每组中 97% 的患者表示他们很满意，并且每组中的所有人都报告说他们没有为远视力、中视力或近视力戴眼镜。结论 屈光性晶状体置换术和三焦点人工晶状体植入术治疗无老花眼患者的远视眼，提供了与老花眼患者相同的良好视觉效果，并且患者满意度和眼镜独立性都很高。[J 屈光手术。2021;37(8):524-531.]。